• CBSA January FOCUS Newsletter: Featuring Fitzsimons Bioscience Park's $8 Expansion and a Sneak Peek at CBSA's Plans for the Upcoming Year
• Denver Business Journal: 'VC-backed startups now free to chase SBIR grant money'
• GEN: 'Cities are trying to attract more talent and incentives to meet demands of the life science industry."
• Coloradoan: 'CSU chemistry prof honored by CBSA'
• 2011 Boettcher Investigators Introduced to Colorado Bioscience Community
• Reminder This Week: BioBeers Denver 4Q11 | Holiday Party Edition!
• Site Selection: 'Colorado Bio has solid infrastructure'
• CSU News & Information: 'Colorado Bioscience Association Names Colorado State University Chemistry Professor Educator of the Year'
…full story

• SUMO-snipping protein plays crucial role in T and B cell development
• 80 percent of 'irreplaceable' habitats in Andes unprotected
• Scientists reveal how cholera bacterium gains a foothold in the gut
• Prejudices? Quite normal!
• Scientists probe form, function of mysterious protein
• What really happened prior to 'Snowball Earth'?
• Researchers shed light on magnetic mystery of graphite
• Making the Blackest of Black Materials
…full story

• UPDATED: Pfizer nabs FDA nod for another targeted cancer drug
• BREAKING: FDA (finally) stamps an approval on Amylin's Bydureon
• Biogen's lead dealmaker makes case against corporate VC
• Merger mania? Or did back-to-back buyouts stoke a media frenzy?
• Big Pharma chiefs balk at bidding against Roche for Illumina
• BioMarin aims to scoop up rare disease drugs as orphan field sizzles
• Infinity craters after lead drug flunks PhII cancer study
• Westphal pulls off a rare stunt with $55M Verastem IPO
…full story

• Cambridge Team First to Grow Smooth Muscle Cells from Patient Skin Cells
• Heptares scientists report the first use of structure-based drug design to discover GPCR-targeted drug candidate
• Heptares granted patents covering stabilised receptor technology in Europe and Japan
• Affectis Granted Patent for AFC-5128, other P2X7 Antagonists
• MediGene Initiates Clinical Formulation Study of RhuDex for the Oral Treatment of Autoimmune Diseases
• Researchers induce Alzheimer's neurons from pluripotent stem cells
• Merck Receives European Approval to Expand Use of Rebif in Patients with Early Multiple Sclerosis
• Rentschler Manufacturing Facility Wins 2012 Facility of the Year Award in Equipment Innovation
…full story

• PolyTherics, Ltd.: Series C $3.5M
• Pharnext, SAS: Series B $3.5M
• Breathe America, Inc.: Series B $22M
• Edison Pharmaceuticals, Inc.: Series E $4.1M
• Zafgen, Inc.: Series C $33M
• Antisense Pharma, GmbH: Series F $11M
• SeeChange Health, Inc.: Series B $20M
• Circle Cardiovascular Imaging, Inc.: Series B $3.9M
…full story

• AMSilk to Be Featured on 21st Century Business Television on CNBC and Fox Business Network
• Rentschler Manufacturing Facility Wins 2012 Facility of the Year Award in Equipment Innovation
• Encap Drug Delivery Adds New Commercial Product to Portfolio
• Affectis Granted Patent for AFC-5128, other P2X7 Antagonists
• Boehringer Ingelheim Prolongates Drug Discovery Collaboration with Priaxon
• Sartorius Stedim Biotech and Refine Technology Announce Cooperation
• Biotage Releases New Catalog and Technical Guide for Sample Preparation and Evaporation
• Sartorius Stedim Biotech and G-Con Manufacturing Announce Global Collaboration
…full story

• A Summary of Mushroom Growing Methods
• Three Good Books About Mushrooms and Other Fungi
• “Now, Forager” Film in Final Production
• A Mid-September Colorado Foray
• Who Will Build the First Vertical Mushroom Farm?
…full story

• New VP for BIO State Government Relations Announced
• 5 Tips From an Accidental Entrepreneur
• Washington Times: McDonnell aims to lure biotech jobs to Virginia
• McDonnell outlines Va job creation initiatives; biotech funding
• Russian Biopharma Conference Features VABIO
• ‘Beer and Biotech’ fosters better relationships
• Lab expansion in BioTech Park bringing 653 new jobs
• Tracking Horse Health Wirelessly
…full story

• In this issue
• Members need only apply
• New Merck and Vertex drugs raise standard of care in hepatitis C
• Biotechs follow big pharma lead back into academia
• Optimer resurrects C. difficile antibiotic to win approval
• New self-reporting for GM crops
• Gates eyes biotechs as for-profit investments …full story

• Types of RNA
• Small Molecule Halts Drug-Resistant Leukemia
• High-Sensitivity Assays Detect New Cancer Biomarkers
• Harvard Bioscience Tops Boston Globe's "Best-of" List
• Rosetta Green Has Solutions to Drought and Biofuel Concerns
• Who Wants to Live Forever?
• Localized Immunosuppression of Islet Transplants Using Stem Cells
• In Defense of Cloning and Stem Cells
…full story

• MorphoSys Strengthens Patent Position on Lead Program MOR103
• EntreMed’s ENMD-2076 Phase 1 Results Demonstrating Activity in Refractory Cancer Patients Accepted for Publication in Clinical Cancer Research
• Peregrine Completes Patient Enrollment in Phase Ib HCV/HIV Coinfection Trial
• MorphoSys Reaches Clinical Milestone with Pfizer
• BioMimetic Therapeutics Announces Date of FDA Advisory Panel Review of Augment(TM) Bone Graft …full story

• Science Daily Biotech: RNA Offers a Safer Way to Reprogram Cells For the first time, researchers have shown that they can deliver those same reprogramming genes using RNA, the genetic material that normally ferries instructions from DNA to the ... > full story …full story

• In this issue
• Biomarkers: the next generation
• Evolving R&D for emerging markets
• News in brief
• Deal watch: CureDM licenses regenerative diabetes therapy to Sanofi–Aventis
• Deal watch: The rise of option agreements
• Trial watch: Adaptive BATTLE trial uses biomarkers to guide lung cancer treatment …full story